Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
PR Newswire —
- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 - - Expanded development of dabogratinib into low-grade upper tract urothelial carcinoma (LG-UTUC); IND cleared with U.S. FDA - - Cash, cash equivalents, and marketable...